STLN (STLN) FinancialsSTLNSTLN

In the context of the broader market, STLN competes directly with industry leaders such as GMRS and FLGT. With a market capitalization of $657.36M, it holds a significant position in the sector. When comparing efficiency, STLN's gross margin of N/A stands against GMRS's 85.68% and FLGT's 27.02%. Such benchmarking helps identify whether Starling Oncology, Inc. is trading at a premium or discount relative to its financial performance.

The company has a P/E ratio of -17.80 and a forward P/E of 0, indicating no expected earnings growth. The price-to-sales ratio is 1.10, which is relatively low, but the overall financial metrics suggest instability.